Matt Winton worked as a consultant for Biogen for three years before joining them. This extended "dating" period allowed both parties to ensure a strong cultural and strategic fit, de-risking his eventual transition into a senior internal role.
CervoMed hired its Chief Commercial Officer before starting Phase III to ensure the trial design supports future commercialization. This avoids the common mistake of treating market access as an afterthought to be "bolted on" after receiving positive data.
CervoMed first secured FDA alignment on its Phase III trial design. It then presented this solidified plan to European and Japanese regulators, which creates a single, consistent global protocol that saves time, money, and avoids market confusion from different labels.
The first commercial priority for a clinical-stage biotech should be payer and health economics (HEOR) research. This ensures the clinical trial includes endpoints that demonstrate clear value to payers, which is essential for future reimbursement and market access.
Inozyme planned to self-commercialize but sold to BioMarin after realizing a larger company with existing infrastructure could get its drug to patients more effectively. This prioritizes the mission over ego, a critical consideration for any startup leadership team.
Small biotechs must consider how pricing decisions in one country could negatively affect a potential acquirer's global portfolio. A misstep can make the company less attractive for M&A, as it could disrupt the larger company's established international pricing structure.
For conditions like dementia, caregivers often make the primary treatment decisions. Commercial strategy and clinical data presentation must be designed to speak directly to them, not just the physician, as their buy-in is crucial for adoption.
Matt Winton left a $3B franchise at Biogen for a startup COO role. His motivation was to shift from supporting board meetings to being directly accountable in them and to move from building a franchise to building an entire company from scratch.
Instead of commissioning expensive, large-scale market research, leaders at small biotechs can gain critical insights by spending hours in direct conversation with physicians. This scrappy, efficient approach uncovers nuanced needs and real-world concerns.